Want to see PGEN full AI Analyst Report?
PGEN Stock Chart & Stats
$3.98
-$0.11(-8.33%)
At close: 4:00 PM EST
$3.98
-$0.11(-8.33%)
Day’s Range― - ―
52-Week Range$1.47 - $6.04
Previous CloseN/A
Volume729.99K
Average Volume (3M)4.93M
Market Cap
$1.76B
Enterprise Value$1.41K
Total Cash (Recent Filing)$56.25M
Total Debt (Recent Filing)$98.25M
Price to Earnings (P/E)―
Beta1.72
Next Earnings
Aug 10, 2026EPS Estimate
-0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.28
Shares Outstanding356,511,000
10 Day Avg. Volume3,762,534
30 Day Avg. Volume4,925,039
Financial Highlights & Ratios
PEG Ratio-0.01
Price to Book (P/B)60.91
Price to Sales (P/S)131.52
P/FCF Ratio-14.18
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$12.50Price Target Upside214.07% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.03
Revenue Forecast (FY)$124.43M
Bulls Say, Bears Say
Bulls Say
Commercial Launch MomentumA rapid first-full-quarter revenue ramp to $21.6M (from $3.4M prior quarter) evidences early product-market fit and commercial traction. Durable adoption in initial launch stages tends to compound as payers, physicians, and hubs optimize workflows, supporting sustained revenue growth over months.
Reimbursement And AccessBroad payer coverage (~297M lives, >90% of insured U.S. lives) plus coding progress materially reduces structural reimbursement friction. Permanent J-code and wide coverage support predictable claims processing, accelerating durable patient access and lowering long-term commercial friction.
Durable Clinical EvidenceClinical durability (median ~3 years) and planned ASCO data reinforce long-term efficacy narrative and clinician confidence. Durable outcomes and upcoming peer-reviewed/meeting data strengthen prescribing rationale and label positioning for sustained uptake across care settings.
Bears Say
Heavy Cash BurnSustained, large negative operating and free cash flows imply the company must convert revenues to cash or access capital to fund operations. Persistent burn drives financing need, increases dilution risk, and constrains investment flexibility in R&D or commercialization if revenues slow.
Elevated LeverageA nearly 5x debt-to-equity ratio marks a meaningful deterioration in balance-sheet flexibility. Elevated leverage raises refinancing and interest-service risk, reducing capacity to withstand revenue volatility and increasing the probability of dilutive or expensive capital options if losses persist.
Low Margins And Persistent LossesLow gross margins (~12% TTM) combined with deep operating and net losses indicate limited current unit economics and constrained ability to absorb SG&A fixed costs. Without margin improvement or diversified revenue streams, profitability remains structurally distant.
Precigen News
PGEN FAQ
What was Precigen, Inc.’s price range in the past 12 months?
Precigen, Inc. lowest stock price was $1.47 and its highest was $6.04 in the past 12 months.
What is Precigen, Inc.’s market cap?
Precigen, Inc.’s market cap is $1.76B.
When is Precigen, Inc.’s upcoming earnings report date?
Precigen, Inc.’s upcoming earnings report date is Aug 10, 2026 which is in 21 days.
How were Precigen, Inc.’s earnings last quarter?
Precigen, Inc. released its earnings results on May 13, 2026. The company reported -$0.02 earnings per share for the quarter, beating the consensus estimate of -$0.034 by $0.014.
Is Precigen, Inc. overvalued?
According to Wall Street analysts Precigen, Inc.’s price is currently Undervalued.
Does Precigen, Inc. pay dividends?
Precigen, Inc. does not currently pay dividends.
What is Precigen, Inc.’s EPS estimate?
Precigen, Inc.’s EPS estimate is -0.01.
How many shares outstanding does Precigen, Inc. have?
Precigen, Inc. has 356,511,000 shares outstanding.
What happened to Precigen, Inc.’s price movement after its last earnings report?
Precigen, Inc. reported an EPS of -$0.02 in its last earnings report, beating expectations of -$0.034. Following the earnings report the stock price went up 10.843%.
Which hedge fund is a major shareholder of Precigen, Inc.?
Currently, no hedge funds are holding shares in PGEN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Precigen Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$12.50 (214.07% Upside)
$12.50 (214.07% Upside)
Blogger Sentiment
Bullish
PGEN Sentiment 70%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Decreased
By 2.1M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $1.1M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.8%
Last 30 Days ▼ 7.8%
Last 30 Days ▼ 7.8%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
171.97%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
7.64%
Trailing 12-Months
Company Description
Precigen, Inc.
Precigen, Inc. is an American company dedicated to the discovery and development of cutting-edge gene and cellular therapies. The company also offers disease-modifying treatments, genetically engineered swine for regenerative medicine, and advanced reproductive and embryo transfer technologies. Its extensive portfolio of proprietary platforms includes UltraVector, which leverages advanced DNA construction and computational modeling to engineer complex gene expression programs; mbIL15, a gene designed to enhance immune cell function; the non-viral Sleeping Beauty transposon/transposase system for genetic modification; and AttSite recombinases, tools for precise DNA recombination. Furthermore, Precigen utilizes its AdenoVerse platform, a library of engineered adenovectors for gene delivery and immunotherapy applications, alongside L. lactis, a food-grade bacterium. The company also provides RheoSwitch, an inducible gene switch system offering quantitative, dose-proportionate control over target protein expression's timing and amount; kill switches, designed to selectively eliminate cell therapies within the body; tissue-specific promoters for targeted gene expression; the UltraCAR-T platform for cancer treatment; and the ActoBiotics platform, which employs genetically modified bacteria to deliver proteins and peptides directly to mucosal sites. Precigen maintains strategic collaboration and license agreements with Alaunos Therapeutics, Inc., Ares Trading S.A., Oragenics, Inc., Castle Creek Biosciences, Inc., and Intrexon Energy Partners I and II, LLC. Established in 1998, Precigen, Inc., previously known as Intrexon Corporation, adopted its current name in January 2020 and is headquartered in Germantown, Maryland.
PGEN Stock 12 Month Forecast
Average Price Target
$12.50
▲(214.07% Upside)
Technical Analysis
MiMedx Group
―
Wave Life Sciences
―
Oric Pharmaceuticals
―
Immunome
―
Praxis Precision Medicines
―
Ownership Overview
35.60% Insiders
11.79% Mutual Funds
0.04% Other Institutional Investors
43.31% Public Companies and
Individual Investors